Etanercept for Post stroke Disability: Practice Advisory
Written By : Dr. Kamal Kant Kohli
Published On 2023-01-17 05:15 GMT | Update On 2023-02-10 10:21 GMT
Advertisement
Stroke is a leading cause of major disability. An inflammatory response may play an important role in ischemic stroke. Some authors have hypothesized that the cytokine tumor necrosis factor (TNF) may play a role in the mediation of inflammatory changes in the ischemic penumbra. Etanercept, a fusion protein consisting of the TNF receptor and the Fc portion of immunoglobulin G, inhibits TNF, thereby diminishing neurotoxic TNF-mediated microglia activation that might contribute to poststroke disability. Moreover, anti-TNF-α blockade has been reported to demonstrate efficacy in stroke animal models.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.